The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer Larry H. MatherlyZhanjun HouAleem Gangjee Review Article 10 November 2017 Pages: 1 - 15
Advances in ovarian cancer therapy Alexander J. CortezPatrycja TudrejKatarzyna M. Lisowska Review Article Open access 16 December 2017 Pages: 17 - 38
Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients L. van AndelH. RosingJ. H. Beijnen Original Article Open access 17 October 2017 Pages: 39 - 46
Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients L. van AndelH. RosingJ. H. Beijnen Correction Open access 27 November 2017 Pages: 47 - 47
Therapeutic potential of the metabolic modulator Metformin on osteosarcoma cancer stem-like cells Daniela I. Paiva-OliveiraSara R. Martins-NevesCélia M. F. Gomes Original Article 30 October 2017 Pages: 49 - 63
Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial) Kiyotaka OkunoToru AoyamaShigetoyo Saji Original Article Open access 01 November 2017 Pages: 65 - 71
A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors Vincent A. de WegerSanjay GoelUlrik Lassen Original Article 03 November 2017 Pages: 73 - 80
Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer Shuji MurakamiHaruhiro SaitoKouzo Yamada Original Article 07 November 2017 Pages: 81 - 87
Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis Ulrike SchmidKarl-Heinz LiesenfeldMatthias Freiwald Original Article Open access 08 November 2017 Pages: 89 - 101
A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer Reiko SakuraiYoshio TomizawaRyusei Saito Original Article 09 November 2017 Pages: 103 - 109
Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review Morikazu MiyamotoMasashi TakanoKenichi Furuya Original Article 09 November 2017 Pages: 111 - 117
DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer Noor Ahmed NahidMohd Nazmul Hasan ApuAbul Hasnat Original Article 13 November 2017 Pages: 119 - 129
The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer Takeshi MasudaChihiro HiranoNoboru Hattori Original Article 15 November 2017 Pages: 131 - 139
Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma Bolag AltanKyoichi KairaKen Shirabe Original Article 17 November 2017 Pages: 141 - 153
Pharmacokinetic and toxicodynamic evaluation of oxaliplatin-induced neuropathy and hematological toxicity in rats Yukako ItoShinji KobuchiYosuke Katsuyama Original Article 21 November 2017 Pages: 155 - 161
Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors Lingaku LeeTetsuhide ItoYoshihiro Ogawa Original Article 21 November 2017 Pages: 163 - 169
Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment Mina NikanjamEdmund V. CapparelliGary Schiller Original Article 22 November 2017 Pages: 171 - 178
Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease L. L. KrensJ. M. BaasH. Gelderblom Original Article Open access 23 November 2017 Pages: 179 - 182
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial Ingrid Jakobsen FalkJohan LundHareth Nahi Original Article Open access 25 November 2017 Pages: 183 - 193
Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects Michael GerischFrank-Thorsten HafnerJohn Lettieri Original Article Open access 29 November 2017 Pages: 195 - 206
The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats Nan LiBin ChenYong-hui Huang Original Article Open access 01 December 2017 Pages: 207 - 216
Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia Ashkan EmadiJennie Y. LawSøren M. Bentzen Short Communication 08 November 2017 Pages: 217 - 222
Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma Michael A. BadruddojaMarjorie PazziMichael Malek Ahmadi Correction 16 October 2017 Pages: 223 - 223
Correction to: Innovative intraoral cooling device better tolerated and equally effective as ice cooling Java WalladbegiMartin GellerstedtMats Jontell Correction 30 October 2017 Pages: 225 - 225